Nov 09, 2010 5:33pm EST OPKO Announces Restatement of Financial Statements to Properly Account for Series D Convertible Preferred Stock; No Impact on Cash, Revenues or Other Results from Operations
Sep 17, 2010 2:35pm EDT CORRECTING and REPLACING OPKO Health to Present at UBS Global Life Sciences Conference
Nov 16, 2009 9:25am EST OPKO Health to Present at the Lazard Capital Markets 6th Annual Healthcare Conference
Nov 11, 2009 8:00am EST OPKO Health Completes Acquisition of NK-1 Compounds from Schering Corporation